Anti-inflammatory therapy reduces wheezing after bronchiolitis

Area of Science:

• Pediatric Pulmonology
• Allergy and Immunology

Background:

• Bronchiolitis is a common viral respiratory infection in infants.
• Wheezing and recurrent respiratory symptoms are frequent sequelae of bronchiolitis.
• Early intervention may mitigate long-term respiratory issues.

Purpose of the Study:

• To investigate the efficacy of early anti-inflammatory therapy using nebulized cromolyn sodium or budesonide in reducing post-bronchiolitis wheezing.
• To assess the impact of these therapies on hospital admissions and symptomatic days.

Main Methods:

• A randomized controlled trial was conducted with 100 infants under 24 months with acute bronchiolitis.
• Participants were assigned to receive nebulized cromolyn sodium, budesonide, or no therapy (control) for 8 weeks.
• Outcomes included physician-diagnosed wheezing episodes, hospital admissions for bronchial obstruction, and parental-reported symptomatic days.

Main Results:

• Both cromolyn sodium and budesonide groups showed significantly fewer wheezing episodes compared to the control group during the second 8-week period.
• Budesonide therapy and treatment in children with atopy led to a significant reduction in hospital admissions.
• Children with atopy experienced more wheezing episodes and hospital admissions, highlighting their increased risk.

Conclusions:

• Nebulized cromolyn sodium and budesonide are effective in reducing wheezing and hospital admissions following bronchiolitis.
• Anti-inflammatory therapy is particularly beneficial for infants with atopy, who are at higher risk for recurrent respiratory symptoms.
• These findings support early anti-inflammatory treatment to improve outcomes after bronchiolitis.